UK government reveals £50M R&D fund as it attempts to assuage drugmakers’ concerns news2025-09-25T13:59:06+00:00September 25th, 2025|Endpoints News|
PepGen seeks funds on the back of early-stage data in muscle wasting diseasenews2025-09-25T10:28:11+00:00September 25th, 2025|Endpoints News|
Hansa’s kidney transplant drug succeeds in Phase 3 trial in USnews2025-09-25T08:36:14+00:00September 25th, 2025|Endpoints News|
Immuneering builds momentum with additional first-line pancreatic cancer data, aims for Phase 3 this yearnews2025-09-24T20:02:25+00:00September 24th, 2025|Endpoints News|
Acadia discards nasal Prader-Willi drug after Phase 3 washoutnews2025-09-24T13:51:34+00:00September 24th, 2025|Endpoints News|
Harmony Biosciences’ cannabidiol drug fails Phase 3 trial in fragile Xnews2025-09-24T13:31:24+00:00September 24th, 2025|Endpoints News|
With successful trial, uniQure eyes 2026 launch for Huntington’s gene therapynews2025-09-24T11:26:50+00:00September 24th, 2025|Endpoints News|
FDA warns J&J vaccine plant in South Korea following 2024 inspectionnews2025-09-23T18:54:28+00:00September 23rd, 2025|Endpoints News|
FDA’s move to update old GSK drug for autism raises questions on dose, supply and datanews2025-09-23T18:23:04+00:00September 23rd, 2025|Endpoints News|
Aera Therapeutics jumps into in vivo CAR-T race with trial planned for 2026news2025-09-23T18:00:33+00:00September 23rd, 2025|Endpoints News|
